Immune Design said the European Medicines Agency has granted Orphan Drug Designation for G100 for the treatment of follicular non-Hodgkin’s lymphoma. G100 has also been granted orphan drug designation by the FDA for the treatment of follicular non-Hodgkin’s lymphoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
